Rheumatol Int. 2021 Aug 06; doi: 10.1007/s00296-021-04955-8. Epub 2021 Aug 06.

Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis.

Rheumatology international

J Hiltunen, P Parmanne, T Sokka, T Lamberg, P Isomäki, O Kaipiainen-Seppänen, R Peltomaa, T Uutela, L Pirilä, K Taimen, M J Kauppi, T Yli-Kerttula, R Tuompo, H Relas, S Kortelainen, K Paalanen, J Asikainen, P Ekman, A Santisteban, K-L Vidqvist, K Tadesse, M Romu, J Borodina, P Elfving, H Valleala, M Leirisalo-Repo, V Rantalaiho, H Kautiainen, T S Jokiranta, K K Eklund,

PMID: 34357455 DOI: 10.1007/s00296-021-04955-8

Abstract

KEY MESSAGES: Considerable proportion of patients with SpA have been immunized to the subcutaneous anti-TNF drug they are using. Concomitant use of MTX protects from immunization, whereas SASP does not. Patients with SpA using subcutaneous anti-TNF drugs can benefit from monitoring of the drug trough levels. Immunization to biological drugs can lead to decreased efficacy and increased risk of adverse effects. The objective of this cross-sectional study was to assess the extent and significance of immunization to subcutaneous tumor necrosis factor (TNF) inhibitors in axial spondyloarthritis (axSpA) patients in real-life setting. A serum sample was taken 1-2 days before the next drug injection. Drug trough concentrations, anti-drug antibodies (ADAb) and TNF-blocking capacity were measured in 273 patients with axSpA using subcutaneous anti-TNF drugs. The clinical activity of SpA was assessed using the Bath AS Disease Activity Index (BASDAI) and the Maastricht AS Entheses Score (MASES). ADAb were found in 11% of the 273 patients: in 21/99 (21%) of patients who used adalimumab, in 0/83 (0%) of those who used etanercept, in 2/79 (3%) of those who used golimumab and in 6/12 (50%) of those who used certolizumab pegol. Use of methotrexate reduced the risk of formation of ADAb, whereas sulfasalazine did not. Presence of ADAb resulted in decreased drug concentration and reduced TNF-blocking capacity. However, low levels of ADAb had no effect on TNF-blocking capacity and did not correlate with disease activity. The drug trough levels were below the consensus target level in 36% of the patients. High BMI correlated with low drug trough concentration. Patients with low drug trough levels had higher disease activity. The presence of anti-drug antibodies was associated with reduced drug trough levels, and the patients with low drug trough levels had higher disease activity. The drug trough levels were below target level in significant proportion of patients and, thus, measuring the drug concentration and ADAb could help to optimize the treatment in SpA patients.

© 2021. The Author(s).

Keywords: Ankylosing spondylitis; Anti-drug antibodies; Biological therapy; Disease activity; Spondyloarthritis; Therapeutic drug monitoring

References

1. de Vries MK, Wolbink GJ, Stapel SO et al (2007) Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 66:1252–1254 - PubMed
2. Méric J-C, Mulleman D, Ducourau E et al (2011) Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study. Ther Drug Monit 33:411–416 - PubMed
3. Ducourau E, Mulleman D, Paintaud G et al (2011) Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 13(3):R105 - PubMed
4. Plasencia C, Pascual-Salcedo D, Nuño L et al (2012) Influence of immunogenicity on the efficacy of long-term treatment of spondyloarthritis with infliximab. Ann Rheum Dis 71:1955–1960 - PubMed
5. de Vries MK, Brouwer E, van der Horst-Bruinsma IE et al (2009) Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 68:1787–1788 - PubMed
6. Kneepkens EL, Wei JC, Nurmohamed MT et al (2015) Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. Ann Rheum Dis 74:396–401 - PubMed
7. Ducourau E, Rispens T, Samain M, Dernis E, Le Guilchard F, Andras L, Perdriger A, Lespessailles E, Martin A, Cormier G, Armingeat T, Devauchelle-Pensec V, Gervais E, Le Goff B, de Vries A, Piver E, Paintaud G, Desvignes C, Ternant D, Watier H, Goupille P, Mulleman D (2020) Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomized trial. RMD Open 6(1):001047. https://doi.org/10.1136/rmdopen-2019-001047 - PubMed
8. Paramarta JE, Baeten DL (2014) Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation. Arthritis Res Ther 16(4):R160 - PubMed
9. Cludts I, Spinelli RF, Morello F, Hockley J, Valesini G, Wadhwa M (2018) Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab. Cytokine 101:70–77 - PubMed
10. Maneiro JR, Salgado E, Gomez-Reino JJ (2013) Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune- mediated inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med 173(15):1416–1428 - PubMed
11. Spinelli FR, Valesini G (2013) Immunogenicity of anti-tumor necrosis factor drugs in rheumatic diseases. Clin Exp Rheumatol 31(6):954–963 - PubMed
12. Bornstein G, Lidar M, Langevitz P et al (2018) The prevalence and clinical effect of immunogenicity of TNF (alpha) blockers in patients with axial SpA. Clin Exp Rheumatol 36:228–232 - PubMed
13. de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT et al (2009) Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 68:531–535 - PubMed
14. Deodhar A, Braun J, Inman RD et al (2015) Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis 74(4):757–761 - PubMed
15. Inman RD, Davis JC Jr, Heijde D et al (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58(11):3402–3412 - PubMed
16. Sieper J, van der Heijde D, Dougados M et al (2015) A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active non-radiographic axial spondyloarthritis. Arthritis Rheum 67(10):2702–2712 - PubMed
17. Sieper J, Landewé R, Rudwaleit M et al (2015) Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial. Arthritis Rheum 67(3):668–677 - PubMed
18. Jani M, Isaacs JD, Morgan AW (2016) High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2015-208849 - PubMed
19. Wolbink GJ, Voskuyl AE, Lems WF et al (2005) Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64(5):704–707 - PubMed
20. Pouw MF, Krieckaert CL, Nurmohamed MT et al (2015) Key findings towards optimizing adalimumab treatment: the concentration-effect curve. Ann Rheum Dis 74(3):513–518 - PubMed
21. Chen D-Y, Chen YM, Tsai W-C et al (2015) Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment. Ann Rheum Dis 74(3):e.16 - PubMed
22. Kneepkens EL, Plasencia C, Krieckaert CL et al (2014) Golimumab trough levels, anti-drug antibodies, and clinical response in patients with rheumatoid arthritis treated in daily clinical practice. Ann Rheum Dis 73(12):2217 - PubMed
23. Jani M, Chinoy H, Warren RB et al (2015) Clinical utility of random anti–tumor necrosis factor drug–level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheum 67(8):2011–2019 - PubMed
24. Goss SL, Klein CE, Jin Z et al (2018) Methotrexate dose in patients with early rheumatoid arthritis impacts methotrexate polyglutamate pharmacokinetics, adalimumab pharmacokinetics, and efficacy: pharmacokinetic and exposure-response analysis of the Concerto trial. Clin Ther 40:309–319 - PubMed
25. Krieckaert CL, Nurmohamed MT, Wolbink GJ (2012) Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 71:1914–1915 - PubMed
26. Krieckaert CLM, Bartelds GM, Lems WF, Wolbink GJ (2010) The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 12(5):217 - PubMed
27. Nam JL, Winthrop KL, van Vollenhoven RF et al (2010) Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69(6):976–986 - PubMed
28. Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA et al (2019) 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 71(10):1599–1613 - PubMed
29. Garcês S, Demengeot J, Benito-Garcia E (2013) The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 72(12):1947–1955 - PubMed
30. Pérez-Guijo VC, Cravo AR, Mdel CC, Font P, Muñoz-Gomariz E, Collantes-Estevez E (2007) Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine 74:254–258 - PubMed
31. Mulleman D, Lauferon F, Wendling D et al (2011) Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. Arthritis Res Ther 13(3):R82 - PubMed
32. Breban M, Ravaud P, Claudepierre P et al (2008) Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 58:88–97 - PubMed
33. Lie E, Kristensen LE, Forsblad-d’Elia H, Zverkova-Sandström T, Askling J, Jacobsson LT, ARTIS Study Group (2015) The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann Rheum Dis 74(6):970–978 - PubMed
34. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 12:2286–2291 - PubMed
35. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A et al (2003) Assessment of enthesistis in ankylosing spondylitis. Ann Rheum Dis 62:127–132 - PubMed
36. Calin A, Garret S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285 - PubMed
37. Bendtzen K (2015) Immunogenicity of anti-TNF-α biotherapies: II. Clinical relevance of methods used for anti-drug antibody detection. Front Immunol 6:109 - PubMed
38. Ducourau E, Ternant D, Lequerré T et al (2014) Towards an individualized target concentration of adalimumab in rheumatoid arthritis. Ann Rheum Dis 73(7):1428–1429 - PubMed
39. Brunner H, Ruperto N, Tzaribachev N et al (2018) Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis 77(1):21–29 - PubMed
40. Gallego JMS, Rosas J, Marco-Mingot M et al (2019) Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis. Rheumatol Int 39(5):841–849 - PubMed
41. van Schouwenburg PA, van de Stadt LA, de Jong RN, van Buren EE, Kruithof S, de Groot E, Hart M, van Ham SM, Rispens T, Aarden L, Wolbink GJ, Wouters D (2013) Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralization. Ann Rheum Dis 72:104–109 - PubMed
42. Bartelds GM, Krieckaert CL, Nurmohamed MT et al (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305(14):1460–1468 - PubMed
43. Arends S, Lebbink HR, Spoorenberg A et al (2010) The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 28(5):661–668 - PubMed
44. van Schouwenburg PA, Rispens T, Wolbink GJ (2013) Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 9(3):164–172 - PubMed
45. Gehin JE, Goll GL, Warren DJ, Syversen SW, Sexton J, Strand EK, Kvien TK, Bolstad N, Lie E (2018) FRI0645 Anti-drug antibodies to certolizumab pegol are associated with low drug levels and reduced clinical response at 3 months in patients with inflammatory joint diseases. Data from the NOR-DMARD study. Ann Rheum Dis 77(Suppl 2):844 - PubMed
46. Rosas J, Llinares-Tello F, Senabre-Gallego JM et al (2017) Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis. Clin Exp Rheumatol 35(1):145–148 - PubMed
47. Micheroli R, Hebeisen M, Wildi LM, Exer P, Tamborrini G, Bernhard J, Möller B, Zufferey P, Nissen MJ, Scherer A, Ciurea A (2017) Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. Arthritis Res Ther 19(1):164 - PubMed
48. Gremese E, Bernardi S, Bonazza S, Nowik M, Peluso G, Massara A, Tolusso B, Messuti L, Miceli MC, Zoli A, Trotta F, Govoni M, Ferraccioli G (2014) Body weight, gender and response to TNF-α blockers in axial spondyloarthritis. Rheumatology 53(5):875–881 - PubMed
49. Singh S, Faggiorusso A, Singh AG et al (2018) Obesity and response to anti-tumor necrosis factor agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS ONE 13(5):e0195123 - PubMed
50. Kneepkens EL, Krieckaert CL, van der Kleij D et al (2015) Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up. Ann Rheum Dis 74(10):1825–1829 - PubMed
51. Jamnitski A, Krieckaert CL, Nurmohamed MT et al (2012) Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 71(1):88–91 - PubMed
52. Pedersen L, Szecsi PB, Bjerrum PJ, Johansen PB (2020) Evaluation of therapeutic drug monitoring in the clinical management of patients with rheumatic diseases: data from a retrospective single-center cohort study. Biologics 14:115–125 - PubMed
53. Martín-López M, Carmona L, Balsa A, Calvo-Alén J, Sanmartí R, Tornero J, Rosas J (2018) Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review. Rheumatol Int 38(6):975–983. https://doi.org/10.1007/s00296-018-4022-4 - PubMed

Publication Types

• Journal Article

Grant support

• WI189027/Pfizer